Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 217

Sort by

Sort Order Select

Journal Articles

Not all that glitters is gold: A simple clinical score to unmask adverse SF3B1WT MDS-RS with low blast count

Marco Gabriele Raddi, Raúl Azibeiro Melchor, Ana Basquiera, Raquel De Paz, Sara Bencini, Giorgio Mattiuz, Lorenzo Tofani, Sven De Pourcq, Angela Consagra, Gloria Andreossi, Maria Diez-Campelo, Francesco Annunziato, Valeria Santini

Blood (2025) 146 (Supplement 1): 5623.

https://doi.org/10.1182/blood-2025-5623

Published: 2025

Journal Articles

Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial

Guillermo Garcia-Manero, Manuel Ugidos, Maroof Hasan, Matthew Stokes, Matteo Della Porta, Amer Zeidan, Valeria Santini, Uwe Platzbecker, Rami Komrokji, Dimana Miteva, Veronika Pozharskaya, Anita Gandhi, Daniel Lopes de Menezes, Rajasekhar Suragani

Blood (2025) 146 (Supplement 1): 5613.

https://doi.org/10.1182/blood-2025-5613

Published: 2025

Journal Articles

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

Uwe Platzbecker, Elena Crisa, Sophie Salazar, Thomas Cluzeau, Antonella Poloni, Raquel De Paz Arias, Thibault Comont, Sebastian Grosicki, Aristoteles Giagounidis, Matteo Della Porta, Pellegrino Musto, Mar Tormo, Dominic Brauer, Ana Alfonso-Pierola, Stefania Paolini, Sophie Park, Annelies Weyn, Lionel Ades, Valeria Santini

Blood (2025) 146 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2025-5649

Published: 2025

Journal Articles

From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS

Sven De Pourcq, Giorgio Mattiuz, Elena Tofacchi, Elettra Celoni, Marco Gabriele Raddi, Gloria Andreossi, Cristina Amato, Luca Rigodanza, Angela Consagra, Valeria Santini

Blood (2025) 146 (Supplement 1): 3866.

https://doi.org/10.1182/blood-2025-3866

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

Luca Lanino, Matteo Zampini, Ivan Civettini, Daniele Ramazzotti, Alessia Campagna, Elena Riva, Denise Ventura, Nicole Pinocchio, Pasquale Niscola, Marco Gabriele Raddi, Angela Consagra, Federica Pilo, Antonella Poloni, Mariarita Sciumè, Andrea Patriarca, Stefania Paolini, Carlo Finelli, Andrea Castelli, Pellegrino Musto, Anna Calvisi, Grazia Sanpaolo, Monia Marchetti, Elisa Diral, Germana Beltrami, Carmen Fava, Claudio Fozza, Chiara Frairia, Carmine Selleri, Daniela Barraco, Domenico Pastore, Rosanna Ciancia, Elena Crisa, Enrico Balleari, Susanna Gallo, Vincenzo Pavone, Esther Natalie Oliva, Giulia Maggioni, Ferdinando Frigeri, Gabriele Todisco, Antonio Russo, Alessandro Buizza, Ivan Ferrari, Giulia Figini, Alessandra Crespi, Elisa Calvetti, Chiara Milanesi, Nicla Manes, Francesco Pesce, Saverio D'Amico, Gianluca Asti, Elisabetta Sauta, Guido Sanguinetti, Gastone Castellani, Marilena Bicchieri, Ilaria Naldi, Francesca Ficara, Valeria Santini, Marta Ubezio, Matteo Della Porta

Blood (2025) 146 (Supplement 1): 3842.

https://doi.org/10.1182/blood-2025-3842

Published: 2025

Journal Articles

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2025-2068

Published: 2025

Journal Articles

Single-cell multi-omics profiling reveals distinct patterns of clonal expansion and microenvironmental shifts associated with disease evolution in patients with Myelodysplastic Syndromes

Matteo Zampini, Elena Riva, Nicolas Sompairac, Giulia Maggioni, Rita Antunes Dos Reis, Rosa Andres Ejarque, Laura Crisafulli, Nicolas Derus, Martina Tarozzi, Claudia Sala, Pamela Acha, Emili Cid Roldós, Elisabetta Sauta, Luca Lanino, Alessia Campagna, Gabriele Todisco, Marta Ubezio, Antonio Russo, Francesco Pesce, Mattia Delleani, Gianluca Asti, Denise Ventura, Cristina Astrid Tentori, Alessandro Buizza, Ivan Ferrari, Matteo Brindisi, Nicole Pinocchio, Elisa Calvetti, Nicla Manes, Chiara Milanesi, Mara Memoli, Federico Caretti, Rongrong Xie, Lorea Chaparro, Caterina Mata, Armando Santoro, Valeria Santini, Amer Zeidan, Rami Komrokji, Paola Guglielmelli, Alessandro Vannucchi, Guillermo Garcia-Manero, Simona Colla, Saverio D'Amico, Guido Sanguinetti, Gastone Castellani, Francesc Sole, Shahram Kordasti, Francesca Ficara, Matteo Della Porta

Blood (2025) 146 (Supplement 1): 3830.

https://doi.org/10.1182/blood-2025-3830

Published: 2025

Journal Articles

Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry

Anna Calvisi, Rosangela Filiberti, Daniela Barraco, Massimo Bernardi, Isabella Capodanno, Andrea Castelli, Rosanna Ciancia, Carmen Fava, Carla Fili, Chiara Frairia, Francesco Frattini, Piero Galieni, Pasquale Niscola, Stefania Paolini, Andrea Patriarca, Anna Maria Pelizzari, Grazia Sanpaolo, Carmine Selleri, Francesco Alesiani, Gianni Binotto, Costanza Bosi, Catello Califano, Barbara Castagnari, Elena Crisa, Monica Crugnola, Marco De Gobbi, Matteo Della Porta, Nicola Di Renzo, Dario Ferrero, Carlo Finelli, Carla Foli, Claudio Fozza, Maurizio Frezzato, Ferdinando Frigeri, Gianluca Guaragna, Monia Marchetti, Daniele G. Mattei, Mara Memoli, Paola Minetto, Alfredo Molteni, Pellegrino Musto, Esther Natalie Oliva, Giuseppe Alberto Palumbo, Fabrizio Pane, Giuseppe Pietrantuono, Federica Pilo, Antonella Poloni, Giulia Rivoli, Mariarita Sciumè, Rodolfo Tassara, Mauro Turrini, Letizia Zannoni, Ilaria Naldi, Enrico Balleari, Valeria Santini, Francesco Onida

Blood (2025) 146 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2025-2080

Published: 2025

Journal Articles

Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology

Blood (2025) 146 (Supplement 1): 396.

https://doi.org/10.1182/blood-2025-396

Published: 2025

Journal Articles

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial

Valeria Santini, Matteo Della Porta, Rami Komrokji, Veronika Pozharskaya, Thalia Farazi, Karen Keeperman, Yinzhi Lai, Dimana Miteva, Tracy Krimmel, Barkha Aggarwal, David Valcarcel, Pierre Fenaux, Jake Shortt, Uwe Platzbecker, Guillermo Garcia-Manero, Amer Zeidan

Blood (2025) 146 (Supplement 1): 792.

https://doi.org/10.1182/blood-2025-792

Published: 2025

Journal Articles

Does stringent cytoreduction improve survival in myeloproliferative chronic myelomonocytic leukemia? a correlative study on the dacota trial.

Blood (2025) 146 (Supplement 1): 791.

https://doi.org/10.1182/blood-2025-791

Published: 2025

Journal Articles

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 790.

https://doi.org/10.1182/blood-2025-790

Published: 2025

Journal Articles

Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus

Blood (2025) 146 (Supplement 1): 789.

https://doi.org/10.1182/blood-2025-789

Published: 2025

Journal Articles

Interim Results of the CMML intercept study: A prospective observational study to evaluate the role of acute inflammation in CMML disease progression

Blood (2025) 146 (Supplement 1): 788.

https://doi.org/10.1182/blood-2025-788

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states

Blood (2025) 146 (Supplement 1): 1440.

https://doi.org/10.1182/blood-2025-1440

Published: 2025

Journal Articles

PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy

Marie Sebert, Valeria Santini, Uwe Platzbecker, David Valcarcel, Uma Borate, Weishi Yuan, Stephanie Kapsalis, Lorene Simonot, Marissa Panzica, Prapti Patel, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 8254.

https://doi.org/10.1182/blood-2025-8254

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Not all that glitters is gold: A simple clinical score to unmask adverse SF3B1WT MDS-RS with low blast count

Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Single-cell multi-omics profiling reveals distinct patterns of clonal expansion and microenvironmental shifts associated with disease evolution in patients with Myelodysplastic Syndromes

Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry

Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial

Does stringent cytoreduction improve survival in myeloproliferative chronic myelomonocytic leukemia? a correlative study on the dacota trial.

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus

Interim Results of the CMML intercept study: A prospective observational study to evaluate the role of acute inflammation in CMML disease progression

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states

PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only